CooperCompanies stock (US21664P1039): Q2 2026 earnings in focus as Nasdaq-listed shares trade near 52-week low
02.06.2026 - 16:51:01 | ad-hoc-news.de
With CooperCompanies heading into its next quarterly report week, the Nasdaq-listed stock remains under scrutiny as investors in the United States weigh upcoming Q2 2026 earnings against a share price that is trading not far above its 52-week low.
According to Nasdaq data, CooperCompanies trades in New York under the ticker COO and closed the latest session modestly lower, with the current 52-week range shown between approximately USD 58.89 and USD 89.66, underscoring the recent pressure on the health-care name.
For Q2 2026, MarketBeat data indicate that CooperCompanies is expected to report earnings around 06/04/2026, continuing its typical early-June pattern for quarterly results.
The company last reported quarterly numbers for Q1 2026 on 03/05/2026, posting earnings per share of USD 1.10, which was above the then-consensus forecast of USD 1.03.
That Q1 2026 release also came with updated guidance, with CooperCompanies outlining an earnings per share range for the period of 4.580 to 4.660 and revenue guidance around USD 4.3 billion, figures that frame investor expectations heading into the new report.
In Germany, CooperCompanies is also accessible to retail investors through venues such as Tradegate and Frankfurt, where the stock recently changed hands around the mid-50s euro range, reflecting similar valuation pressure to the US listing and offering a bridge for euro-based investors following the Nasdaq move.
As of: 02/06/2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: CooperCompanies
- Sector/industry: Health care, medical devices (contact lenses and women’s health)
- Headquarters/country: San Ramon, United States
- Core markets: North America, Europe, and Asia-Pacific eye-care and women’s health markets
- Key revenue drivers: Soft contact lenses for vision correction and specialty uses, plus fertility and obstetrics products
- Home exchange/listing venue: Nasdaq (COO)
- Trading currency: USD
CooperCompanies: core business model
CooperCompanies focuses on eye-care and women’s health solutions, with sales largely generated by its CooperVision contact lens portfolio and CooperSurgical products used in fertility clinics and obstetrics settings.
Latest quarterly results for CooperCompanies at a glance
The most recent reported figures for CooperCompanies date back to Q1 2026, when the company released its numbers on 03/05/2026 and posted earnings per share of USD 1.10 versus a consensus estimate of USD 1.03, according to MarketBeat.
Alongside that Q1 2026 release, CooperCompanies issued guidance indicating an earnings per share range of 4.580 to 4.660 and revenue guidance around USD 4.3 billion for the relevant period, setting a numerical backdrop that investors will compare against the upcoming Q2 2026 report expected around 06/04/2026.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on CooperCompanies
Ahead of the expected Q2 2026 earnings release, online discussions and video content frequently focus on how CooperCompanies balances growth in premium contact lenses with macro and pricing headwinds in health care.
Conclusion
With Q2 2026 results expected shortly and Q1 2026 having delivered EPS of USD 1.10 alongside guidance for EPS of 4.580 to 4.660 and revenue of about USD 4.3 billion, CooperCompanies enters its next earnings event with clearly defined benchmarks.
Nasdaq trading data showing the stock near the lower half of its 52-week range highlight how the coming report may influence sentiment on the United States-listed health-care name for both domestic and German-based investors following the contact lens and women’s health specialist.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
